Late effects toxicity scoring: The soma scale

Pavy, JJ; Denekamp, Juliana; Letschert, J.G.J.; Littbrand, Bo; Mornex, F.; Bernier, Jacques; Gonzales-Gonzales, D; Horiot, Jean-Claude; Bolla, M.; Bartelink, Harry

doi:10.1016/0360-3016(95)00059-8

Cited by 246 publications

(68 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The objective SOMA scales (0 -4) (Pavy et al, 1995) were used to score for fibrosis, atrophy and telangiectasia severity during a detailed physical examination and represent separate phenotypic measures of late normal tissue damage. The SOMA scores of 1 represent subtle examiner-dependent changes that are inconclusive and in this study are either excluded or included in the group of patients that show no signs (SOMA 0) of a particular injury phenotype.…”

Section: Resultsmentioning

confidence: 99%

“…The Late Effects of Normal Tissue-Subjective Objective Management Analytical (LENT-SOMA) scale allows comparison between individuals of the clinical perception of injury, the patient's perception of the injury, the medical management required and the underlying pathological process (Pavy et al, 1995). A score of 0-4 is given to each of the LENT-SOMA tests, and the sum of the individual scores for each patient a measure of overall tissue damage.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes

et al. 2007

View full text Add to dashboard Cite

The relationship between late normal tissue radiation injury phenotypes in 167 breast cancer patients treated with radiotherapy and: (i) radiotherapy dose (boost); (ii) an early acute radiation reaction and (iii) genetic background was examined. Patients were genotyped at single nucleotide polymorphisms (SNPs) in eight candidate genes. An early acute reaction to radiation and/or the inheritance of the transforming growth factor-b1 (TGFb1 À509T) SNP contributed to the risk of fibrosis. In contrast, an additional 15 Gy electron boost and/or the inheritance of X-ray repair cross-complementing 1 (XRCC1) (R399Q) SNP contributed to the risk of telangiectasia. Although fibrosis, telangiectasia and atrophy, all contribute to late radiation injury, the data suggest that they have distinct underlying genetic and radiobiological causes. Fibrosis risk is associated with an inflammatory response (an acute reaction and/ or TGFb1), whereas telangiectasia is associated with vascular endothelial cell damage (boost and/or XRCC1). Atrophy is associated with an acute response, but the genetic predisposing factors that determine the risk of an acute response or atrophy have yet to be identified. A combined analysis of two UK breast cancer patient studies shows that 8% of patients are homozygous (TT) for the TGFb1 (C-509T) variant allele and have a 15-fold increased risk of fibrosis following radiotherapy (95% confidence interval: 3.76 -60.3; P ¼ 0.000003) compared with (CC) homozygotes.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Indeed, the CTC Version 2, the Dische system, Franco-Italian Glossary, UCLA Cancer Index and RTOG/EORTC have all been shown to have shortcomings (Shakespeare et al, 1998;Yeoh et al, 2000;Anacak et al, 2001;Livsey et al, 2002;Trotti, 2002). More recently, the Late Effects Normal Tissue (LENT) SOMA questionnaire (Pavy et al, 1995;Rubin et al, 1995) has been proposed, and while overcoming many of the problems of earlier questionnaires, it is much more complex and requires a lengthy, structured interview with a patient, which is often not feasible.…”

mentioning

confidence: 99%

A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy

et al. 2005

View full text Add to dashboard Cite

After radiotherapy for pelvic cancer, chronic gastrointestinal problems may affect quality of life (QOL) in 6 -78% of patients. This variation may be due to true differences in outcome in different diseases, and may also represent the inadequacy of the scales used to measure radiotherapy-induced gastrointestinal side effects. The aim of this study was to assess whether outcome measures used for nonmalignant gastrointestinal disease are useful to detect gastrointestinal morbidity after radiotherapy. Results obtained from a Vaizey Incontinence questionnaire and a modified Inflammatory Bowel Disease questionnaire (IBDQ) -both patient completed -were compared to those from a staff administered Late Effects on Normal Tissue (LENT) -Subjective, Objective, Management and Analytic (SOMA) questionnaire in patients who had completed radiotherapy for a pelvic tumour at least 3 months previously. In all, 142 consecutive patients were recruited, 72 male and 70 female, median age 66 years (range 26 -90 years), a median of 27 (range 3 -258) months after radiotherapy. In total, 62 had been treated for a gynaecological, 58, a urological and 22, a gastrointestinal tract tumour. Of these, 21 had undergone previous gastrointestinal surgery and seven suffered chronic gastrointestinal disorders preceding their diagnosis of cancer. The Vaizey questionnaire suggested that 27% patients were incontinent for solid stools, 35% for liquid stools and 37% could not defer defaecation for 15 min. The IBDQ suggested that 89% had developed a chronic change in bowel habit and this change significantly affected 49% patients: 44% had more frequent or looser bowel movements, 30% were troubled by abdominal pain, 30% were troubled by bloating, 28% complained of tenesmus, 27% were troubled by their accidental soiling and 20% had rectal bleeding. At least 34% suffered emotional distress and 22% impairment of social function because of their bowels. The small intestine/colon SOMA median score was 0.1538 (range 0 -1) and the rectal SOMA median score was 0.1428 (range 0 -1). Pearson's correlations for the IBDQ score and small intestine/colon SOMA score was À0.630 (Po0.001), IBDQ and rectum SOMA À0.616 (Po0.001), IBDQ and Vaizey scores À0.599 (Po0.001), Vaizey and small intestine/colon SOMA 0.452 (Po0.001) and Vaizey and rectum SOMA 0.760 (Po0.001). After radiotherapy for a tumour in the pelvis, half of all patients develop gastrointestinal morbidity, which affects their QOL. A modified IBDQ and Vaizey questionnaire are reliable in assessing new gastrointestinal symptoms as well as overall QOL and are much easier to use than LENT SOMA.

show abstract

“…The severity of the adverse reactions was scored for each patient using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 2.0 (6), the grading system of the Radiation Therapy Oncology Group (RTOG) (7), and the decrease in the white blood cell (WBC) and platelet (PLT) counts. Other widely used scoring systems include those of the RTOG and European Organization for Research and Treatment of Cancer, and the Late Effects Normal Tissue Task Force (8). These scales include four separate elements, representing subjective, objective, management and analytical evaluation of injury (Table II).…”

Section: Resultsmentioning

confidence: 99%

Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer

Dang

Huang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate the curative effect of gamma knife stereotactic body radiotherapy (SBRT) for unresectable massive primary liver cancer. A total of 69 patients with unresectable massive (>10 cm) primary liver cancer who were treated by SBRT at the Department of Radiation Oncology of the 323 Hospital of People's Liberation Army (Xi'an, China) between October, 2006 and October, 2010, were analyzed. According to the Union for International Cancer Control TNM staging guidelines, the patients were graded as stage T1 (n=8), T2 (n=12), T3 (n=21) and T4 (n=28). None of the patients had lymph node metastasis, whereas 45 patients had portal vein tumor thrombosis. The Child-Pugh class was A (n=49), B (n=15) and C (n=5). The visible tumor volume ± standard deviation was 810±213 cm 3 . The patients received a total radiation dose of 50-60 Gy, with a dose fractionation of 4-6 Gy/fx, administered for a total of 9-12 times, 2-5 times/week. A total of 8 patients succumbed to the disease within 3 months after gamma knife treatment and were not included in the evaluation of the curative effect. The total effectiveness rate was 59.0% (36/61) and the median survival was 17.4 months for all the patients included in the study. The 1-, 2-, and 3-year overall survival rates were 71, 30 and 22%, respectively. In conclusion, SBRT appears to be effective for unresectable massive primary liver cancer.

show abstract

Late effects toxicity scoring: The soma scale

Cited by 246 publications

References 2 publications

The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes

The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes

A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy

Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer

Contact Info

Product

Resources

About